Vagifem

ApprovedSmall molecule

Novo Nordisk

Vagifem is one of 92 small molecule programs targeting Recurrent urinary tract infections. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Urinary Tract InfectionsActive, not recruiting

AtrophyActive, not recruiting

Endometrial CancerActive, not recruiting

Recurrent Urinary Tract InfectionsApproved

Active, not recruiting

AtrophyPhase 3

Active, not recruiting

Endometrial CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

258 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

55 2

Keytruda

Merck & Co.

Phase 3

20 3

Femara

Novartis

Phase 3

19 4

Paraplatin

AAvyxa

Phase 3

38 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

26 6

Adriamycin

Pfizer

Phase 3

8 7

Lynparza

AstraZeneca

Phase 3

7 8

Lenvima

Eisai

Phase 3

6 9

Tecentriq

Roche

Phase 3

4 10

Trodelvy

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalActive, not recruiting

Recurrent Urinary Tract Infections

NCT06353269

Clinical

Trials by Indication[1]

Vaginal Dryness1 trial

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active, not recruiting·PPolly A. Niravath, MD·Phase 2·NCT01984138·33 enrolled

Recurrent urinary tract infections1 trial

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Active, not recruiting·UUniversity of California, Irvine·Phase 4·NCT06353269·111 enrolled

Endometrial Cancer1 trial

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

Completed· Novo Nordisk logo

Novo Nordisk··NCT05243823·500,000 enrolled

Atrophy1 trial

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

Completed·GGlenmark Pharmaceuticals Ltd. India·Phase 3·NCT02668796·522 enrolled

Trial1 trial

The Vaginal Health Trial

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT02516202·302 enrolled

1 more indication

Surgery1 trial

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

Withdrawn·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT02860897

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Vagifem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vagifem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vagifem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novo Nordisk

Vagifem

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Vaginal Dryness1 trial

Recurrent urinary tract infections1 trial

Endometrial Cancer1 trial

Atrophy1 trial

Trial1 trial

Surgery1 trial

References

Drug Info

Quick Facts

Related News